CrushSCI.com
141.1平均天数
125中位天数
53最短天数
274最长天数
3502025发文量

Paper Review Records

全部论文审稿周期

19 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期;保留 PDF/DOI/网页源链接

64 天

Treatment outcomes and quality of life with palbociclib in patients with advanced breast cancer who also have other medical conditions: a plain language summary of findings from POLARIS

作者
Debu Tripathy; Joanne L. Blum; Meghan S. Karuturi; Steven McCune; Sobha Kurian; Mehdi M. Moezi; Daniel M. Anderson; Yan Ji; Timothy J. Pluard; John Migas; Shailendra Lakhanpal; Erin Jepsen; Yao Wang; Monica Z. Montelongo; Zhe Zhang; Joseph C. Cappelleri; Eric Gauthier; Gabrielle B. Rocque展开收起
作者单位
1. aDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 2. bDepartment of Oncology, Baylor-Sammons Cancer Center, Texas Oncology, US Oncology, Dallas, TX, USA; 3. cWilliam S. Gibbons Cancer Research Institute, Northwest Georgia Oncology Centers Wellstar, Marietta, GA, USA; 4. dHematology/Oncology, West Virginia University Cancer Institute, Morgantown, WV, USA; 5. eMedical Oncology, Cancer Specialists of North Florida, Fleming Island, FL, USA; 6. fOncology & Hematology, Health Partners Institute, Saint Paul, MN, USA; 7. gHealth Partners Institute, Saint Paul, MN, USA; 8. hSaint Luke’s Cancer Institute, Kansas City, MO, USA; 9. iMid-Illinois Hematology & Oncology Associates Ltd, Normal, IL, USA; 10. jSaint Vincent’s Birmingham, Birmingham, AL, USA; 11. kNovant Health, Winston-Salem, NC, USA; 12. lOncology Medical Group, Pfizer Inc, New York, NY, USA; 13. mBiostatistics and Medical Writing, ICON Commercialization and Outcomes, ICON Plc., Blue Bell, PA, USA; 14. nOncology Clinical Statistics, Pfizer Inc, San Diego, CA, USA; 15. oStatistical Research and Data Science Center, Pfizer Inc, Groton, CT, USA; 16. pGlobal Medical Affairs, Pfizer Inc, San Francisco, CA, USA; 17. qDivision of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA展开收起
PDF源文件 DOI 网页
53 天

Study design of the phase III ADELA trial of elacestrant with or without everolimus in ESR1 -mutated ER+/HER2– advanced breast cancer after progression on endocrine therapy plus a CDK4/6 inhibitor

作者
José Manuel Pérez-García; Antonio Llombart-Cussac; Elena López-Miranda; Alfonso Cortes; Isabel Garcia; Elena Galve-Calvo; Manuel Ruiz-Borrego; Alba Cochs; Antonia Perelló-Martorell; Serafin Morales; Laia Boronat Ruiz; Sara Marín-Liébana; Cristina Saavedra; Isabel Blancas; Carmen Hinojo; Mariana López Flores; Sylvain Ladoire; Peter Schmid; Gilles Freyer; Rui Rui Zhang; Daniel Alcalá-López; Juliana Carvalho-Santos; Olga Boix; Carlos H. Barrios; Giuseppe Curigliano; Rupert Bartsch; Anne Clair Hardy Bessard; Tomer Wasserman; Javier Cortés展开收起
作者单位
1. Barcelona (Spain); 2. Quiron Group; 3. Medical Oncology Department, Hospital Arnau de Vilanova, FISABIO; 4. Universidad Cardenal Herrera-CEU; 5. Hospital Universitario Ramón y Cajal (IRYCIS); 6. Department of Radiology, Hospital Clínic i Provincial de Barcelona; 7. Medical Oncology Department, Hospital Universitario de Basurto; 8. Virgen del Rocío University Hospital; 9. Hospital Universitari Sant Joan de Reus; 10. Medical Oncology Department, Hospital Universitari Son Espases; 11. Medical Oncology Department, Hospital Universitario Arnau de Vilanova de Lleida; 12. Medical Oncology Department, Institut Català d’ Oncologia Badalona (ICO); 13. Hospital Beata Maria Ana; 14. Medical Oncology Department, Hospital Universitario San Cecilio Clinic; 15. Granada University; 16. Translational and Integrative Oncology, Instituto de Investigación Biosanitaria de Granada (ibs.Granada); 17. Medical Oncology Department, Hospital Universitario Marqués de Valdecilla – Instituto de Investigación Valdecilla (IDIVAL); 18. Medical Oncology Department, Hospital Universitario de León; 19. Centre Georges-François Leclerc; 20. Barts Cancer Institute, Queen Mary University of London, London; 21. Medical Oncology Department, Barts Hospital NHS Trust; 22. Medical Oncology Department, Centre Hospitalier Lyon-Sud Hospices Civils de Lyon; 23. Oncology Research Center, Latin American Cooperative Oncology Group (LACOG) - Porto Alegre, Brazil Oncoclinicas Group; 24. University of Milano; 25. Medical University of Vienna; 26. CARIO-HPCA, UNICANCER; 27. Global Medical Affairs, Menarini Group; 28. Department of Medicine展开收起
PDF源文件 DOI 网页
225 天

Falcon – multicancer early detection (MCED) real-world evidence (RWE) registry

作者
Ronan J. Kelly; Peter J. Hulick; Henry Mark Dunnenberger; Mindi Styn; Jessica Profato-Partlow; Deb Kettner-Sieber; Michelle A. Beidelschies; Sara Jackson; Pratima R. Bakshi; William T. Christensen; Jahnave Gudaru; Akira S. Numajiri; Khang N. Tran; Vijay Parthasarathy; Tomasz M. Beer展开收起
作者单位
1. Baylor University Medical Center; 2. Mark R. Neaman Center for Personalized Medicine, Endeavor Health; 3. Abbott Cancer Diagnostics; 4. Baylor Scott & White MedProvider; 5. Baylor Scott & White Family Medical Center-Riverside; 6. Baylor Scott & White Primary Care at the Star展开收起
PDF源文件 DOI 网页
274 天

Protocol for a multicenter prospective phase II trial of adjuvant tislelizumab combined with S-1 in subjects with residual primary lesions and node-negative esophageal squamous cell carcinoma (PPIO-008)

作者
Ying-Jian Wang; Xv Chen; Xian-Feng Xie; Chang-Feng Li; Tao Bao; Xian-Dong He; Kun-Kun Li; Xiang-Shu Pu; Yan He; Wei Guo展开收起
作者单位
1. Army Medical Center of People’s Liberation Amry of China (Daping Hospital)展开收起
PDF源文件 DOI 网页
56 天

A plain language summary of results from the NeoADAURA study: treatment with osimertinib before surgery for patients with EGFR-mutated non-small cell lung cancer that can be surgically removed

作者
Jianxing He; Walter Weder; Ke-Neng Chen; Maximilian J. Hochmair; Jin-Yuan Shih; Sung Yong Lee; Kang-Yun Lee; Viet Nhung Nguyen; Somcharoen Saeteng; Lunxu Liu; Ligang Xing; Nguyen Hoang Gia; Shuji Murakami; Yongtao Han; María Paz Saavedra; Seong Hoon Yoon; Carlos H.A. Teixeira; Carles Escriu; Alex Martinez-Martí; Collin M. Blakely; Yasushi Yatabe; Sanja Dacic; Yuri Rukazenkov; Xiangning Huang; Anupriya Dayal; Jamie E. Chaft; for the NeoADAURA Investigators展开收起
作者单位
1. aDepartment of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, China State Key Laboratory of Respiratory Disease & National Clinical Research Centre for Respiratory Disease, Guangzhou, China; 2. bDepartment of Thoracic Surgery, University of Zurich, Thoracic Surgery, Clinic Bethanien, Zurich, Switzerland; 3. cState Key Laboratory of Molecular Oncology, Beijing Key Laboratory of Carcinogenesis and Translational Research, The First Department of Thoracic Surgery, Peking University Cancer Hospital & Institute, Beijing, China; 4. dKarl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna, Austria; 5. eDepartment of Respiratory and Critical Care Medicine, Klinik Floridsdorf, Vienna Healthcare Group, Vienna, Austria; 6. fDepartment of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; 7. gDivision of Pulmonary Medicine, Department of Internal Medicine, Korea University Guro Hospital, Seoul, Republic of Korea; 8. hDivision of Pulmonary Medicine, Department of Internal Medicine, Shuang-Ho Hospital, Taipei Medical University, Taipei, Taiwan; 9. iVietnam National Lung Hospital, Faculty of Medicine, UMP, VNU, Hanoi, Vietnam; 10. jDepartment of Surgery, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; 11. kDepartment of Thoracic Surgery, West China Hospital of Sichuan University, Chengdu, China; 12. lDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China; 13. mDepartment of Medical Oncology, Hanoi Oncology Hospital, Hanoi, Vietnam; 14. nDepartment of Thoracic Oncology, Kanagawa Cancer Canter, Yokohama, Japan; 15. oDepartment of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China; 16. pOrlandi Oncología, Santiago, Chile; 17. qDepartment of Internal Medicine, Pusan National University, School of Medicine, and Yangsan Hospital, Yangsan, Republic of Korea; 18. rClinical Oncology Department, Hospital Alemão Oswaldo Cruz, São Paulo, Brazil; 19. sDepartment of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK; 20. tDepartment of Medical Oncology, Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, UK; 21. uDepartment of Medical Oncology, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital, Barcelona, Spain; 22. vDepartment of Medicine, University of California, San Francisco, CA, USA; 23. wHelen Diller Comprehensive Cancer Center, University of California, San Francisco, CA, USA; 24. xDepartment of Diagnostic Pathology, National Cancer Center, Tokyo, Japan; 25. yDepartment of Pathology, Yale School of Medicine, New Haven, CT, USA; 26. zLate-stage Development, Oncology R&D, AstraZeneca, Cambridge, UK; 27. aaBiometrics, Late-stage Development, Oncology R&D, AstraZeneca, Cambridge, UK; 28. bbLate-stage Development, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA; 29. ccThoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA; 30. ddDepartment of Medicine, Weill Cornell Medical College, New York, NY, USA展开收起
PDF源文件 DOI 网页
173 天

Plain language summary of the ReNeu study: a study of mirdametinib for adults and children with neurofibromatosis type 1 (NF1) who have plexiform neurofibromas

作者
Angela Hirbe; Christopher L Moertel; Dusica Babovic-Vuksanovic; Claas Röhl; Kim Bischoff; Kate Kelts; Abraham J Langseth; Michael D Weber; Beverly Oberlander; Adli Wunderlich; Julie Jared; Timothy R Gershon展开收起
作者单位
1. aDivision of Oncology, Washington University, St. Louis, MO, USA; 2. bDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA; 3. cMayo Clinic, Rochester, MN, USA; 4. dNF Patients United – Global Network of NF Patient Organisations, The Netherlands; 5. eNeurofibromatosis Network, IL, USA; 6. fChildren’s Tumor Foundation, NY, USA; 7. gSpringWorks Therapeutics, Inc, a healthcare company of Merck KGaA, Darmstadt, Germany; Stamford, CT, USA; 8. hPatient and Caregiver Author; 9. iPatient Author; 10. jCaregiver Author; 11. kDepartment of Pediatrics, Emory University, Atlanta, GA, USA展开收起
PDF源文件 DOI 网页

FAQ

Future Oncology审稿要多久?

截至2026-11-19,CrushSCI 收录了 Future Oncology 的 19 篇完整审稿记录。最快一篇从收稿到录用用了 53 天(Study design of the phase III ADELA trial of elacestrant with or without everolimus in ESR1 -mutated ER+/HER2– advanced breast cancer after progression on endocrine therapy plus a CDK4/6 inhibitor,2026-08-28 收稿,2026-10-20 录用),最慢一篇用了 274 天;平均 141.1 天,中位数 125 天。

Expert Matching · Case Demo

把投稿要求,转成可验证的期刊方案

说清专业、时限和作者背景,CrushSCI 结合真实审稿样本,给出拟题方向、期刊初筛与周期判断。

我们会在半小时内回复。

CrushSCI 在线

客户询问

我是环境工程专业,需要一篇 SCI,希望 3 个月内见刊。没有基金,也没有大牛挂名,可以投哪些期刊?

CrushSCI回复

可以。先按 90 天时限做可行性筛选,同步查找无基金、无知名作者挂靠的典型论文案例,作为选刊依据。重点核对研究质量与期刊 scope。

拟题建议
《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》

样本口径2026 年最近 5 篇有效论文样本

平均审稿59.6 天

中位数65 天

Contact CrushSCI

联系 CrushSCI

留下手机号或微信号,我们将与你确认学术润色、结构优化或一对一辅导咨询需求。

我们会在半小时内回复。

当前选择:学术咨询服务

预留联系方式

也可以直接发送邮件至 leader@crushsci.com

手机号和微信号至少填写一项,仅用于本次咨询联系,不会公开。